AIM
RCUS icon

AXA Investment Managers’s Arcus Biosciences RCUS Stock Holding History

AXA Investment Managers’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.16M Buy
+232,668
New +$2.42M 0.01% 671

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXA Investment Managers's RCUS Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Arcus Biosciences (RCUS) in Q3 2025: 232,668 shares worth $3.16M. The stake represents 0.01% of the portfolio and ranks #671 among its holdings.

190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • AXA Investment Managers held 232,668 shares of Arcus Biosciences worth $3.16M as of Q3 2025.
  • Arcus Biosciences was a new AXA Investment Managers position in Q3 2025.
  • Arcus Biosciences made up 0.01% of AXA Investment Managers's portfolio in Q3 2025, its #671 holding.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.